Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y. Kashyap T, et al. Among authors: argueta c. Oncotarget. 2016 Nov 29;7(48):78883-78895. doi: 10.18632/oncotarget.12428. Oncotarget. 2016. PMID: 27713151 Free PMC article.
Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.
Gravina GL, Mancini A, Colapietro A, Marampon F, Sferra R, Pompili S, Biordi LA, Iorio R, Flati V, Argueta C, Landesman Y, Kauffman M, Shacham S, Festuccia C. Gravina GL, et al. Among authors: argueta c. Oncotarget. 2017 Nov 30;8(67):111225-111245. doi: 10.18632/oncotarget.22760. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340049 Free PMC article.
Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.
Aboukameel A, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI, Azmi AS. Aboukameel A, et al. Among authors: argueta c. Oncotarget. 2018 Oct 19;9(82):35327-35342. doi: 10.18632/oncotarget.26239. eCollection 2018 Oct 19. Oncotarget. 2018. PMID: 30450161 Free PMC article.
Correction: Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.
Gravina GL, Mancini A, Colapietro A, Marampon F, Sferra R, Pompili S, Biordi LA, Iorio R, Flati V, Argueta C, Landesman Y, Kauffman M, Shacham S, Festuccia C. Gravina GL, et al. Among authors: argueta c. Oncotarget. 2019 Oct 29;10(59):6393-6395. doi: 10.18632/oncotarget.27289. eCollection 2019 Oct 29. Oncotarget. 2019. PMID: 31695847 Free PMC article.
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.
Fischer MA, Friedlander SY, Arrate MP, Chang H, Gorska AE, Fuller LD, Ramsey HE, Kashyap T, Argueta C, Debler S, Byrne M, Villaume MT, Shaver AC, Senapedis W, Landesman Y, Baloglu E, Shacham S, Savona MR. Fischer MA, et al. Among authors: argueta c. Blood Adv. 2020 Feb 11;4(3):586-598. doi: 10.1182/bloodadvances.2019000359. Blood Adv. 2020. PMID: 32045477 Free PMC article.
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC. Fulciniti M, et al. Among authors: argueta c. Blood. 2017 Apr 20;129(16):2233-2245. doi: 10.1182/blood-2016-06-724831. Epub 2017 Jan 17. Blood. 2017. PMID: 28096095 Free PMC article.
33 results